Table 1.
Current clinical trials based on NK cell checkpoint receptors or molecules.
| Checkpoint receptor | Ab | Combination | Malignancy | Phase | Status | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| KIR | IPH4102 | Cutaneous T-cell lymphoma | I | Active | NCT02593045 | |
| Lirilumab | Nivolumab (anti-PD1 Ab) |
Bladder cancer | I | Recruiting | NCT03532451 | |
| Lirilumab | Nivolumab (anti-PD1 Ab)/Ipilimumab (anti-CTLA-4 Ab) |
Advanced and/or metastatic solid tumors | I | Active | NCT03203876 | |
| Lirilumab | Nivolumab (anti-PD1 Ab) |
Advanced cancer | I | Recruiting | NCT03335540 | |
| BMS-986015 | Ipilimumab (anti-CTLA-4 Ab) |
Advanced tumor | I | Completed | NCT01750580 | |
| 1-7F9 | Multiple myeloma | I | Completed | NCT00552396 | ||
| Lirilumab | Nivolumab (anti-PD1 Ab)/Ipilimumab (anti-CTLA-4 Ab) |
Advanced refractory solid tumors | I/II | Completed | NCT01714739 | |
| Lirilumab | Nivolumab (anti-PD1 Ab)/Ipilimumab (anti-CTLA-4 Ab) |
Solid tumors | I/II | Active | NCT03347123 | |
| Lirilumab | Nivolumab (anti-PD1 Ab) |
Multiple myeloma | I/II | Active | NCT01592370 | |
| Lirilumab | Rituximab | Acute myeloid leukemia | I/II | Recruiting | NCT01256073 | |
| Lirilumab | Nivolumab (anti-PD1 Ab) |
Squamous cell carcinoma of the head and neck | II | Recruiting | NCT03341936 | |
| Lirilumab | Rituximab (anti-CD20 Ab) |
Lymphocytic leukemia | II | Completed | NCT02481297 | |
| IPH2101 | Smoldering multiple myeloma | II | Completed | NCT01222286 | ||
| IPH2101 | Multiple myeloma | II | Completed | NCT00999830 | ||
| IPH4102 | Gemcitabine and oxaliplatin | Advanced T cell lymphoma | II | Recruiting | NCT03902184 | |
| NKG2A | Monalizumab | Hematologic malignancies | I | Recruiting | NCT02921685 | |
| Monalizumab | Gynecologic cancer | I | Completed | NCT02459301 | ||
| Monalizumab | Chronic lymphocytic leukemia | I/II | Terminated | NCT02557516 | ||
| Monalizumab | Cetuximab (anti-EGFR Ab) |
Head and neck neoplasms | I/II | Recruiting | NCT02643550 | |
| Monalizumab | Durvalumab (anti-PD-L1 Ab) |
Advanced solid tumors | I/II | Active | NCT02671435 | |
| Monalizumab | Stage III non-small cell lung cancer | II | Recruiting | NCT03833440 | ||
| Monalizumab | Durvalumab (anti-PD-L1 Ab) |
Carcinoma/Squamous cell of head and neck | II | Recruiting | NCT03088059 | |
| TIGIT | OMP-313M32 | Locally advanced/Metastatic cancer | I | Terminated | NCT03119428 | |
| AB154 | AB122(anti-PD1 Ab) | Advanced malignancies | I | Recruiting | NCT03628677 | |
| MTIG7192A | Atezolizumab (anti-PD1 Ab) |
Advanced/Metastatic tumors | I | Recruiting | NCT02794571 | |
| MTIG7192A | Atezolizumab (anti-PD1 Ab) |
Non-small cell lung cancer | II | Active | NCT03563716 | |
| TIM-3 | Sym023 | Metastatic/Solid tumor, lymphoma | I | Active | NCT03489343 | |
| TSR-022 | Advanced/Metastatic solid tumors | I | Recruiting | NCT02817633 | ||
| RO7121661 | Solid tumors, metastatic melanoma, non-small cell lung cancer | I | Recruiting | NCT03708328 | ||
| LY3321367 | Solid tumor | I | Active | NCT03099109 | ||
| MBG453 | Spartalizumab (anti-PD1 Ab) |
Glioblastoma multiforme | I | Active | NCT03961971 | |
| MBG453 | Acute myeloid leukemia | I | Recruiting | NCT03940352 | ||
| MBG453 | PDR001 (anti-PD1 Ab) |
Leukemia | I | Recruiting | NCT03066648 | |
| INCAGN02390 | Advanced malignancies | I | Recruiting | NCT03652077 | ||
| BGB-A425 | Tislelizumab (anti-PD1 Ab) |
Locally advanced/metastatic solid tumors | I/II | Recruiting | NCT03744468 | |
| MBG453 | PDR001 (anti-PD1 Ab) |
Advanced malignancies | I/II | Recruiting | NCT02608268 | |
| TSR-022 | TSR-042 (anti-PD1 Ab) |
Liver cancer | II | Recruiting | NCT03680508 | |
| LAG-3 | Sym022 | Metastatic cancer, solid tumor, lymphoma | I | Completed | NCT03489369 | |
| TSR-033 | Advanced solid tumors | I | Recruiting | NCT03250832 | ||
| BMS-986016 | Nivolumab (anti-PD1 Ab) |
Glioblastoma | I | Recruiting | NCT02658981 | |
| BMS-986016 | Nivolumab (anti-PD1 Ab) |
Glioblastoma | I | Recruiting | NCT03493932 | |
| REGN3767 | REGN2810 (anti-PD1 Ab) |
Malignancies | I | Recruiting | NCT03005782 | |
| MGD013 | Advanced solid tumors, hematologic neoplasms | I | Recruiting | NCT03219268 | ||
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Advanced solid tumors | I | Active | NCT02966548 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Gastric cancer, cancer of the stomach | I | Active | NCT03662659 | |
| Relatlimab | Nivolumab (anti-PD1 Ab)/Carboplatin/ Paclitaxel/Radiation |
Gastric/Esophageal Cancer | I | Recruiting | NCT03044613 | |
| FS118 | Advanced/Metastatic cancer | I | Active | NCT03440437 | ||
| IMP321 | Solid tumors | I | Recruiting | NCT03252938 | ||
| IMP321 | Renal cell carcinoma | I | Completed | NCT00351949 | ||
| IMP321 | Metastatic breast cancer | I | Completed | NCT00349934 | ||
| IMP321 | Pembrolizumab (anti-PD1 Ab) |
Melanoma | I | Completed | NCT02676869 | |
| BMS-986016 | Hematologic neoplasms | I/II | Active | NCT02061761 | ||
| Relatlimab | Solid tumors | I/II | Recruiting | NCT01968109 | ||
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Various advanced cancer | I/II | Active | NCT02488759 | |
| IMP321 | Paclitaxel | Adenocarcinoma breast stage IV | II | Active | NCT02614833 | |
| IMP321 | Pembrolizumab (anti-PD1 Ab) |
Non-small cell lung carcinoma, head and heck carcinoma | II | Recruiting | NCT03625323 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Melanoma | II | Recruiting | NCT03743766 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Advanced chordoma | II | Recruiting | NCT03623854 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Advanced cancer | II | Active | NCT02750514 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Advanced cancer | II | Recruiting | NCT02996110 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Advanced gastric cancer | II | Recruiting | NCT02935634 | |
| Relatlimab | Nivolumab (anti-PD1 Ab) |
Melanoma | II/III | Recruiting | NCT03470922 | |
| PD-1 | Pembrolizumab | Advanced solid tumor | I | Recruiting | NCT03590054 | |
| Pembrolizumab | IL-12 | Metastatic solid tumor, Unresectable solid tumor |
I | Recruiting | NCT03030378 | |
| Pembrolizumab | BDB001 (TLR agonist) |
Solid tumor | I | Recruiting | NCT03486301 | |
| TSR-042 | Neoplasms | I | Recruiting | NCT02715284 | ||
| Nivolumab Pembrolizumab | iPSC-derived NK Cells | Advanced solid tumors | I | Recruiting | NCT03841110 | |
| Pembrolizumab | DC-NK Cells | Solid tumor | I | Not yet recruiting | NCT03815084 | |
| Nivolumab | NK Cells | Renal cell carcinoma | I | Recruiting | NCT03891485 | |
| Toripalimab | Solid tumors | I | Completed | NCT02857166 | ||
| Toripalimab | Advanced solid tumors | I | Enrolling by invitation | NCT03713905 | ||
| Toripalimab | Advanced malignancies | I | Recruiting | NCT03474640 | ||
| Toripalimab | Melanoma/Urological cancer | I | Active | NCT02836795 | ||
| JS001 | Surufatinib (anti-VEGFR Ab) |
Advanced solid tumors | I | Recruiting | NCT03879057 | |
| HLX10 | Solid tumor | I | Recruiting | NCT03468751 | ||
| LZM009 | Solid tumor | I | Completed | NCT03286296 | ||
| GB226 | Advanced and (or) recurrent solid tumor, lymphoma |
I | Recruiting | NCT03374007 | ||
| INCMGA00012 | Advanced solid tumors | I | Recruiting | NCT03059823 | ||
| AK105 | Advanced cancer | I | Recruiting | NCT03352531 | ||
| SG001 | Advanced solid tumors | I | Not yet recruiting | NCT03852823 | ||
| CS1003 | Solid tumor, lymphoma | I | Recruiting | NCT03809767 | ||
| SCT-I10A | Solid tumor, lymphoma | I | Recruiting | NCT03821363 | ||
| Sym021 | Sym022 (anti-LAG3 Ab)/Sym023 (anti-TIM3 Ab) |
Advanced solid tumors, lymphomas | I | Recruiting | NCT03311412 | |
| Nivolumab | BGB-290 (PARP inhibitor) |
Advanced solid tumors | I | Active | NCT02660034 | |
| Nivolumab | BGB-A1217 (anti-TIGIT Ab) |
Advanced solid tumors | I | Recruiting | NCT04047862 | |
| Nivolumab | RGX-104 | Advanced solid malignancies, lymphoma | I | Recruiting | NCT02922764 | |
| Avelumab | DC1c + myeloid DC + Ipilimumab | Neoplasms | I | Recruiting | NCT03707808 | |
| ABBV-181 | Rovalpituzumab (anti-delta-like 3 protein)/Venetoclax |
Advanced solid tumors | I | Recruiting | NCT03000257 | |
| Sintilimab | IBI310 | Advanced solid tumors | I | Recruiting | NCT03545971 | |
| SHR-1210 | SHR3162 (Parp inhibitor) |
Advanced solid tumors | I | Unknown | NCT03182673 | |
| JNJ 63723283 | anti-FGFR1-4 | Neoplasms | I | Recruiting | NCT03547037 | |
| Pembrolizumab | Allogeneic NK Cells | Biliary tract cancer | I/II | Recruiting | NCT03937895 | |
| Pembrolizumab | Autologous DC-CIK cell | Advanced solid tumors | I/II | Recruiting | NCT03190811 | |
| Pembrolizumab | Lenalidomide | Non-small cell lung cancer | I/II | Terminated | NCT02963610 | |
| Pembrolizumab | MRx0518 | Solid tumors | I/II | Recruiting | NCT03637803 | |
| Pembrolizumab | lymphoma | I/II | Recruiting | NCT02535247 | ||
| Pembrolizumab | AGEN1884 | Advanced solid cancers | I/II | Recruiting | NCT02694822 | |
| Pembrolizumab | AST-008 (TLR9 agonist) |
Advanced solid tumors | I/II | Recruiting | NCT03684785 | |
| Pembrolizumab | Poly-ICLC | Metastatic colon Cancer | I/II | Recruiting | NCT02834052 | |
| Tislelizumab | BGB-A333 (anti PD-L1 Ab) |
Advanced solid tumors | I/II | Active | NCT03379259 | |
| Nivolumab | Ipilimumab/BMS-986218 | Advanced solid tumors | I/II | Recruiting | NCT03110107 | |
| Nivolumab | BMS-986207 (anti-TIGIT Ab) |
Advanced solid tumors | I/II | Recruiting | NCT02913313 | |
| Nivolumab | Relatlimab/Ipilimumab + BMS-986205 (IDO1 inhibitor) |
Advanced cancer | I/II | Recruiting | NCT03459222 | |
| Nivolumab | Adenoviral product (Ad-p53) +pembrolizumab/capecitabine |
Metastatic solid tumor, recurrent head and neck cancer |
I/II | Recruiting | NCT02842125 | |
| Nivolumab | RP1 (Genetically modified HSV for tumor lysis) |
Melanoma/Bladder cancer, Non-melanoma skin cancer |
I/II | Recruiting | NCT03767348 | |
| PD-1 Ab | NK Cells | Non-small cell lung cancer | II | Recruiting | NCT03958097 | |
| Avelumab | haNKTM | Merkel cell carcinoma | II | Recruiting | NCT03853317 | |
| Pembrolizumab | Merkel cell carcinoma | II | Recruiting | NCT03241927 | ||
| Pembrolizumab | Advanced solid tumor | II | Recruiting | NCT02721732 | ||
| Pembrolizumab | Metastatic, recurrent or locally advanced cancer | II | Recruiting | NCT03428802 | ||
| Pembrolizumab | Advanced non-small cell lung carcinoma | II | Recruiting | NCT03447678 | ||
| Pembrolizumab | Nab-paclitaxel + anti-cancer drugs | Malignant Neoplasm of Breast | II | Active | NCT03289819 | |
| HX008 | Advanced solid tumors | II | Recruiting | NCT03704246 | ||
| Tislelizumab | MSI-H/dMMR solid tumors | II | Recruiting | NCT03736889 | ||
| Nivolumab | Metformin/Rosiglitazone | Solid tumor malignancies | II | Not yet recruiting | NCT04114136 | |
| Nivolumab | Ipilimumab | Advanced solid tumors | II | Recruiting | NCT02834013 | |
| Nivolumab | Axitinib (anti-VEGF Ab) |
Renal cell carcinoma | II | Recruiting | NCT03595124 | |
| Nivolumab | Relatlimab (anti-LAG-3 Ab)Ipilimumab (anti-CTLA-4 Ab) |
Head and neck cancer | II | Recruiting | NCT04080804 | |
| Nivolumab | Pembrolizumab + trigriluzole (PKC inhibitor) |
Metastatic/Unresectable malignancies, lymphoma | II | Recruiting | NCT03229278 | |
| AGEN2034 | AGEN1884 | Cervical cancer | II | Recruiting | NCT03894215 | |
| PD-L1 | HLX20 | Advanced solid tumors | I | Recruiting | NCT03588650 | |
| KN035 | Advanced/Metastatic solid tumors | I | Unknown | NCT03248843 | ||
| KN035 | Hepatocellular carcinoma | I | Unknown | NCT03101488 | ||
| Atezolizumab | Neoplasms | I | Recruiting | NCT02862275 | ||
| CS1001 | Advanced solid tumors | Ia/Ib | Recruiting | NCT03312842 | ||
| MSB2311 | Advanced solid tumors | I | Recruiting | NCT03463473 | ||
| SHR-1316 | Advanced solid tumors | I | Completed | NCT03133247 | ||
| CK-301 | Advanced cancers | I | Recruiting | NCT03212404 | ||
| LY3300054 | Prexasertib (CHK1 inhibitor) |
Advanced solid tumors | I | Active | NCT03495323 | |
| Durvalumab | Tremelimumab + stereotactic body radiotherapy | Non-small cell lung cancer | Ib | Recruiting | NCT03275597 | |
| Durvalumab | Tremelimumab +metronomic vinorelbine | Advanced solid tumors | I/II | Suspended | NCT03518606 | |
| Durvalumab | Tremelimumab + azacitidine | Head and neck cancer | I/II | Recruiting | NCT03019003 | |
| Avelumab | Utomilumab + PF-04518600 + radiation therapy | Advanced malignancies | I/II | Recruiting | NCT03217747 | |
| Durvalumab | Tremelimumab + fulvestrant | Breast cancer | II | Unknown | NCT03430466 | |
| Durvalumab | Tremelimumab + radiation therapy | Bladder cancer | II | Recruiting | NCT03601455 | |
| Durvalumab | Tremelimumab | Advanced solid tumors | III | Active | NCT03084471 | |
| CD73/A2AR | Ciforadenant | CPI-006 | Advanced cancers | I | Recruiting | NCT03454451 |
| MEDI9447 | MEDI4736 | Solid tumors | I | Active | NCT02503774 | |
| Ciforadenant | Atezolizumab | Renal cell cancer, Metastatic castration resistant prostate cancer | I | Recruiting | NCT02655822 | |
| Ciforadenant AZD4635 |
Durvalumab (anti-PD-1 Ab) |
Advanced solid malignancies | I | Recruiting | NCT02740985 | |
| NZV930 NIR178 |
PDR001 | Advanced malignancies | I | Recruiting | NCT03549000 | |
| PBF-509: | PDR001 | Non-small cell lung cancer | I/II | Recruiting | NCT02403193 | |
| Oleclumab AZD4635 |
Osimertinib | Non-small cell lung cancer | I/II | Active | NCT03381274 | |
| NIR178 | PDR001 | Solid tumors, Non-Hodgkin lymphoma |
II | Recruiting | NCT03207867 |